Tevogen Bio Holdings Inc. (TVGN) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed on June 21, 2024, covering events occurring on June 14 and June 15, 2024. Tevogen Bio Holdings Inc., a Delaware corporation and emerging growth company, reported two material events: the repurchase of Series B Preferred Stock and a notification from Nasdaq regarding non-compliance with minimum bid price requirements.
Key Financial Metrics
The filing does not provide standard financial performance metrics such as revenue, profit, cash flow, or operating margins. The primary financial disclosure relates to a specific transaction:
- Liability Reassumption: The Company reassumed liabilities of $3.6 million previously assigned to SSVK Associates, LLC.
- Balance Sheet Impact: Management stated that the reassumption of these liabilities would not have increased the liabilities reflected on the Company's balance sheet as of March 31, 2024.
- Debt and Liquidity: No specific figures regarding total debt, cash reserves, or liquidity ratios are provided in this filing.
Material Changes and Events
Preferred Stock Repurchase (Item 1.01): On June 15, 2024, the Company entered into a Repurchase Agreement with SSVK Associates, LLC (a beneficial owner of over 5% of common stock and whose managing member sits on the Board). The Company repurchased and cancelled all outstanding shares of Series B Preferred Stock held by SSVK. In consideration, the Company reassumed $3.6 million in liabilities and terminated the prior Assignment and Assumption Agreement.
Nasdaq Delisting Notice (Item 3.01): On June 14, 2024, the Company received notice from Nasdaq that it failed to meet the $1.00 minimum bid price requirement for 35 consecutive business days. The stock continues to trade, but the Company has 180 calendar days (until December 11, 2024) to regain compliance.
Outlook, Risks, and Contingencies
Compliance Risk: The Company faces the risk of delisting if it cannot maintain a closing bid price of $1.00 or more for 10 consecutive business days before the December 11, 2024 compliance date. Failure to comply may result in a transfer to the Nasdaq Capital Market or potential delisting.
Management Commentary: The Company intends to actively monitor the stock price and evaluate options to regain compliance. However, management explicitly stated there can be no assurance that compliance will be achieved or that listing rules will be maintained.
Investor Verification Checklist
- Verify the current closing bid price of TVGN common stock to assess the likelihood of meeting the $1.00 threshold within the 180-day window.
- Review the full text of the Preferred Stock Repurchase Agreement (Exhibit 10.1) to understand the specific nature of the $3.6 million liabilities reassumed.
- Monitor future filings for any reverse stock split announcements or other corporate actions intended to address the Nasdaq bid price deficiency.
- Confirm the Company's cash position in the most recent Form 10-Q to evaluate its ability to fund operations while addressing the delisting risk.